ENLV — Enlivex Therapeutics Balance Sheet
0.000.00%
- $27.99m
- $4.56m
- 20
- 34
- 17
- 13
Annual balance sheet for Enlivex Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 12 | 35.7 | 84.1 | 50.2 | 27.3 |
Net Total Receivables | 2.4 | 0 | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 16.4 | 38.1 | 86.4 | 52.3 | 33.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.06 | 2.14 | 8.22 | 14.9 | 2.58 |
Other Long Term Assets | |||||
Total Assets | 17.6 | 40.4 | 95.1 | 67.6 | 36.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.98 | 4.37 | 4.72 | 6.61 | 6.06 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.28 | 4.87 | 10.1 | 10.8 | 6.75 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 11.3 | 35.5 | 85 | 56.8 | 30.1 |
Total Liabilities & Shareholders' Equity | 17.6 | 40.4 | 95.1 | 67.6 | 36.8 |
Total Common Shares Outstanding |